Phase 2b Clinical Trial for APPA, Osteoarthritis (OA) Treatment,  Ahead of Schedule

A 225 patient Phase 2b clinical trial commenced in July 2024 in multiple centres in Denmark and in Hong Kong.  The trial is focused on patients with more severe osteoarthritis (OA), which aligns with patients who reported significant reduction in pain in the Phase 2a trial. As of mid-October 2024, the trial is running ahead of schedule with more than 50% of the planned number of patients enrolled in the 90-day dosing trial.

APPA is a highly differentiated oral Phase 2 clinical OA drug. With a novel mechanism of action, APPA targets the multiple signalling pathways in bone, cartilage and inflammation that are involved in OA.  APPA, being an oral drug, is more convenient for long term patient use than injectables. It is being investigated for its effectiveness in bringing pain relief to multiple joints.

Headline results from the study are due late 3Q 2025.

About AKL

  • AKL Therapeutics, is a privately held, pharmaceutical company, with an innovative approach to drug development
  • AKL Research & Development Limited, trading as AKL Therapeutics, is based at the Stevenage Bioscience Catalyst, Stevenage, Herts UK.
  • AKL identifies and synthesizes secondary metabolites of plant origin with proven efficacy & safety. This innovative approach greatly increases the chances of success, while reducing the probability of unexpected side effects.
  • The development process is led by an expert management team with a high level of technical, scientific and strategic skill.
  • AKL is focused on developing its lead clinical asset APPA, a novel therapeutic for inflammatory diseases where there is a high unmet need, including osteoarthritis (OA) and other complex diseases of ageing.
  • APPA has the potential to be a groundbreaking oral treatment for human & animal osteoarthritis.